Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Yixinshu is a Traditional Chinese Medicine (TCM) formulation primarily used for the treatment of cardiovascular conditions, including coronary heart disease and angina pectoris. The formula typically consists of seven herbal ingredients: *Panax ginseng* (人参), *Ophiopogon japonicus* (麦冬), *Schisandra chinensis* (五味子), *Salvia miltiorrhiza* (丹参), *Astragalus membranaceus* (黄芪), *Crataegus pinnatifida* (山楂), and *Carthamus tinctorius* (红花). It is designed to replenish Qi, nourish Yin, and promote blood circulation to resolve stasis. Clinically, it is employed to alleviate symptoms such as chest tightness, palpitations, and shortness of breath associated with Qi and Yin deficiency. The drug is manufactured in various forms, including tablets and pills, by companies such as Guangxi Yulin Pharmaceutical.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Yixinshu.